Approximately 20% to 30% of all people who suffer from psoriasis also develop painful inflammation in their joints over time.

Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in active PsA and obesity.

Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.

The TOGETHER-PsA study shows that combining ixekizumab with tirzepatide leads to significantly better psoriatic arthritis ...

UCB Canada Inc. is pleased to announce Health Canada has granted a Notice of Compliance (NOC) for PrBIMZELX® (bimekizumab injection) indicated for the treatment ...

Discover effective strategies to manage arthritis pain during winter, including diet, exercise, and warmth for improved ...

Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

Arthritis is a broad term that covers conditions in which joints become inflamed, painful, and often less mobile. Many people ...

SKYWAY (NCT07148414) is a Phase 2 basket trial of SPY072 (anti-TL1A) in patients with moderate to severely active RA, PsA, or axSpA. Enrollment is on track, and all indications are expected to readout ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial ...